WIPO - 国際・国内特許データベース検索

1.WO/2023/159316FORMULATION OF ANTI-SARS-COV-2 NEUTRALIZING ANTIBODIES AND USES THEREOF

WO - 31.08.2023

国際特許分類 (IPC) A61K 39/42 出願番号 PCT/CA2023/050235 出願人 IMMUNE BIOSOLUTIONS INC. 発明者 FUGÈRE, Alexandre

The present application relates to a composition comprising a combination of anti-SARS- CoV-2 antibodies or antigen-binding fragments thereof, or of nucleic acids encoding the anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. Methods and uses of the compositions for the prevention and/or treatment of betacoronavirus infections and related diseases such as COVID-19, are also described. The compositions may be administered in the respiratory tract, e.g., in nebulized or aerosolized form, to subjects infected with or at risk of being infected with a coronavirus such as SARS-CoV-2.

2.20230357366Antigen Binding Molecules Targeting SARS-CoV-2

US - 09.11.2023

国際特許分類 (IPC) C07K 16/10 出願番号 18313306 出願人 Generate Biomedicines, Inc. 発明者 Francesco Borriello

The disclosure provides, in various embodiments, polypeptides (e.g., antibodies and antigen binding fragments thereof) that specifically bind to S2 domains of betacoronavirus Spike glycoproteins, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike glycoproteins. The disclosure also provides, in various embodiments, fusion proteins comprising one or more of polypeptides, polynucleotides encoding polypeptides, vectors and host cells suitable for expressing polypeptides, and methods for treating viral infections (e.g., COVID-19).

3.WO/2022/099187SARS-COV-2 ANTIGEN-BINDING PROTEINS AND USES THEREOF

WO - 12.05.2022

国際特許分類 (IPC) A61P 11/00 出願番号 PCT/US2021/058593 出願人 PRESIDENT AND FELLOWS OF HARVARD COLLEGE 発明者 ABRAHAM, Jonathan

The present invention provides severe acute respiratory syndrome coronavirus (SARS-CoV), e.g., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen- binding proteins, pharmaceutical compositions, and methods of use thereof to passively immunize and treat subjects having or at risk of having a SARS-CoV, e.g., SARS-CoV-2, infection.

4.WO/2024/086566PAN-SARBECOVIRUS NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOF

WO - 25.04.2024

国際特許分類 (IPC) C07K 16/10 出願番号 PCT/US2023/077073 出願人 THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 発明者 PULENDRAN, Bali

Provided herein are antibodies and antigen binding fragments that are capable of binding to a betacoronavirus, e.g. a sarbecovirus selected from one or more of SARS-CoV-2, SARS-CoV-2 omicron, SARS-CoV-2 beta, SARS-CoV-1, WIV-1, RaTG13, and SCH014.

5.WO/2022/015573SARS-COV-2 ANTIGEN-BINDING PROTEINS AND USES THEREOF

WO - 20.01.2022

国際特許分類 (IPC) A61K 39/42 出願番号 PCT/US2021/040900 出願人 PRESIDENT AND FELLOWS OF HARVARD COLLEGE 発明者 ABRAHAM, Jonathan

The present invention provides severe acute respiratory syndrome coronavirus (SARS-CoV), e.g., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen-binding proteins and methods of use thereof to passively immunize and treat subjects having or at risk of having a SARS-CoV, e.g., SARS-CoV-2, infection.

6.20210353620Method of treating severe acute respiratory syndrome (SARS) virus infection by administering a protein disulfide isomerase (PDI) inhibitor

US - 18.11.2021

国際特許分類 (IPC) A61K 31/496 出願番号 17320069 出願人 The University of Vermont and State Agricultural College 発明者 Vikas Anathy

Compositions and methods involving protein disulfide isomerase (PDI) inhibitors, such as protein disulfide isomerase A3 (PDIA3) inhibitory compounds, for human coronavirus, such as severe acute respiratory syndrome (SARS) virus (e.g., SARS-CoV-2), therapies are disclosed herein.

7.WO/2024/026553NOVEL ANTIGENIC EPITOPE AGAINST SARS-COV-2 AND USES THEREOF

WO - 08.02.2024

国際特許分類 (IPC) C07K 14/165 出願番号 PCT/CA2022/051182 出願人 CENTRE HOSPITALIER DE L'UNIVERSITÉ DE MONTRÉAL 発明者 FINZI, Andrés

The present application discloses antigenic peptides that are recognized by neutralizing anti-SARS-CoV-2 antibodies. Neutralizing antibodies targeting these antigenic peptides are effective against several SARS-CoV-2 variants. Conjugates, vesicles, pharmaceutical compositions and vaccines comprising the antigenic peptides, as well as antibodies recognizing these antigenic peptides, are also disclosed. The antigenic peptides and encoding nucleic acids, conjugates, antibodies or antigen-binding fragments thereof, vesicles, pharmaceutical compositions or vaccines described herein may be used for the prevention and/or treatment of coronavirus infection and/or associated diseases and symptoms, such as SARS-CoV-2 infection and/or COVID-19.

8.WO/2021/206638VACCINE AND/OR ANTIBODY FOR VIRAL INFECTION

WO - 14.10.2021

国際特許分類 (IPC) C07K 14/165 出願番号 PCT/SG2021/050197 出願人 INTRA-IMMUSG PRIVATE LIMITED 発明者 ZENG, Qi

The present invention relates to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) N-protein and/or an immunogenic fragment thereof and uses thereof. The invention also includes a nucleic acid molecule encoding the SARS-CoV-2 N-protein and/or an immunogenic fragment thereof; and uses thereof. The SARS-CoV-2 N protein and/or immunogenic fragment thereof may be produced by recombinant DNA technology or may be chemically synthesised. In particular, the SARS-CoV-2 N-protein and/or an immunogenic fragment thereof and/or nucleic acid molecule encoding the SARS-CoV-2 N-protein and immunogenic may be for use as a vaccine. The invention further includes an antibody capable of binding to the SARS-CoV-2 N-protein or antigen-binding fragment thereof and uses thereof.

9.WO/2006/086561NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME-ASSOCIATED CORONAVIRUS

WO - 17.08.2006

国際特許分類 (IPC) A61K 39/00 出願番号 PCT/US2006/004599 出願人 NEW YORK BLOOD CENTER 発明者 JIANG, Shibo

The present invention provides an isolated antibody capable of binding to the receptor- binding domain of the spike protein of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) so as to competitively inhibit the binding of the SARS-CoV to host cells. These mAbs or substances can be used: 1) as passive-immunizing agents for prevention of SARS-CoV infection; 2) as biological reagents for diagnosis of SARS-CoV infection; 3) as immunotherapeutics for early treatment of SARS-CoV infection; and 4) as probes for studying the immunogenicity, antigenicity, structure, and function of the SARS- CoV S protein.

10.WO/2023/039577BROADLY NEUTRALIZING NANOBODIES FOR CORONAVIRUS AND USES THEREOF

WO - 16.03.2023

国際特許分類 (IPC) C07K 16/10 出願番号 PCT/US2022/076293 出願人 UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 発明者 SHI, Yi

Disclosed herein are coronavirus neutralizing antibodies and uses thereof for treating and/or preventing a coronavirus infection in a subject.

1 / 160

検索入力欄に移動	`CTRL` + `SHIFT` +
結果一覧に移動	`CTRL` + `SHIFT` +
文献詳細に移動	`CTRL` + `SHIFT` +
次のページに進む	`CTRL` +
前のページに戻る	`CTRL` +

次の文献/図に移動	/
前の文献/図に移動	/
上へスクロール	`Page Up`
下へスクロール	`Page Down`
一番上までスクロール	`CTRL` + `Home`
一番下までスクロール	`CTRL` + `End`

処理中

国内段階移行

公報目録 (オーソリティファイル)

設定

ご意見・ご感想

出願の表示

検索式の保存

検索式のツリー表示

条件の絞込み

検索式全体

この画面で利用可能なショートカットキー

結果分析

次のタブに移動
前のタブに移動

処理中